Francois Gouin

We wish to apologize for a incorrectly cited reference in our article, High Rate of Ceramic Sandwich Liner Fracture published in Clinical Orthopaedics and Related Research in 2012, Volume 470, pages 1705–1720. Reference 8, as we cited in the text and in Table 4, by Ha et al. is incorrect. The correct citation should be Ha YC, Kim SY, Kim HJ, Yoo JJ, Koo KH. Ceramic liner fractures after cementless alumina-on-alumina total hip arthroplasty. Clin Orthop Relat Res. 2007;458:106–110. We apologize for this error and thank Dr. Ha for bringing this error to our attention.

Tural rigidity was introduced. Fractures of these devices also were reported subsequently, although the incidence is unclear and it is unknown whether there are any risk factors associated with the fractures. Questions/purposes We therefore determined the incidence of these fractures. Methods We retrospectively reviewed 298 active patients in whom we implanted 353 ceramic-polyethylene sandwich liner acetabular components between November 1999 and February 2008. The mean age of the patients was 53.6 years (range, 17-84 years). The minimum followup was 6 months (mean, 41 months; range, 6-106 months). All patients were assessed clinically and radiographically. Results Seven of the 353 (2%) ceramic sandwich liners fractured at a mean of 4.3 years (range, 1.3-7.6 years) after surgery without trauma. Neither patient-related factors nor radiographic position of the implants were risk factors for fracture. Conclusions Owing to the high rate of fractures of the sandwich ceramic polyethylene liners in our patients, we have discontinued use of this device. Level of Evidence Level IV, therapeutic study. See Guidelines for Authors for a complete description of levels of evidence....

Chondrosarcoma is a difficult musculoskeletal tumor to treat. Surgical treatment leads to severe disability, with high rates of local recurrence and life threat. No adjuvant therapy is effective in differentiated chondrosarcomas. Bisphosphonates (BPs) are a class of molecules which is effective in malignant bone diseases. The aim of the present study was to determine the effects of zoledronic acid (ZOL) on chondrosarcoma tumor progression. ZOL was tested in vivo (s.c. 100 μg/kg, twice a week) in a rat chondrosarcoma model and in vitro (10⁻⁷–10⁻⁴ M) on cells derived from this model. Two types of animal models were assessed, the first simulated development after intralesional curettage, the second nonoperative development of the tumor. Cell proliferation, caspase‐1, ‐3 activities and cell cycle analysis were studied. The results revealed that ZOL slows down primary tumor development, tumor progression after intralesional curretage and increases overall survival. ZOL inhibits cell proliferation and increases cell death, with no significant variation of caspase‐1 and ‐3 activities and cell cycle profiles. The present study demonstrates for the first time that in addition to surgery, the therapy of chondrosarcoma with BPs might be beneficial. Because of these first results, new therapeutic approaches of chondrosarcoma must be considered, mainly for low grade chondrosarcoma when disabling operation is planned and when only intralesional resection can be undertaken.